Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Leukemic cutaneous T-cell lymphomas (L-CTCL) are aggressive cancers with poor outcomes.
• Genomic studies reveal frequent chromosomal alterations but lack identified driver mutations.
• Chronic inflammation and tissue damage contribute to high L-CTCL mortality.

Purpose of the Study:

• To identify key molecular vulnerabilities in L-CTCL.
• To explore novel therapeutic targets by integrating genomic and pharmacologic data.
• To investigate the role of STAT3/5 oncogenes and PAK kinases in L-CTCL pathogenesis.

Main Methods:

• Genomic landscape analysis of L-CTCL patient samples.
• Pharmacologic interference using small-molecule degraders and multi-kinase inhibitors.
• In vitro and ex vivo assessment of L-CTCL cell growth.
• In vivo efficacy studies using xenograft mouse models.

Main Results:

• Copy number gains of STAT3/5 oncogene loci were found in 74% of L-CTCL cases.
• Dual inhibition of STAT3/5 pathways significantly reduced L-CTCL cell proliferation.
• PAK kinase inhibition selectively targeted L-CTCL cells with STAT3/5 gains.
• The PAK inhibitor FRAx597 demonstrated anti-leukemic activity in vivo, reducing tumor growth and dissemination.

Conclusions:

• STAT3/5 and PAK kinase signaling pathways represent a critical therapeutic node in L-CTCL.
• Targeting this interaction with agents like FRAx597 shows potential for L-CTCL treatment.
• Further exploration of STAT3/5 and PAK kinase inhibition is warranted for L-CTCL therapy.